Oncology Medical News about PET/CT

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

PET/CT for the staging and follow-up of patients with malignancies
European Journal of Radiology, 06/22/09

Poeppel TD et al. – Review discusses the methodological issues in positron emission tomography (PET) and computed tomography (CT) and the main oncological indications of ¹⁸F-labelled fluoro-deoxy-d-glucose (FDG)-PET/CT.

PET and CT complement each other's strengths in integrated PET/CT
The standard whole-body imaging simplifies tumour staging and speeds up decision processes to determine appropriate therapeutic strategies
PET/CT is of high value as the primary staging and restaging modality in many tumour entities
PET/CT may also be useful for malignant melanoma, gynaecologic tumours, iodine-negative thyroid carcinoma, GIST, malignant bone tumours, testicular cancer, sarcomas, etc.
New PET-tracers in clinical routine will continually increase the number of PET/CT indications:
- ¹⁸F-choline for imaging of prostate cancer
- ⁶⁸Ga-labelled somatostatin analogues for imaging of differentiated neuroendocrine tumours